peptide glp 1 GLP-1 Drugs and the Physiology of Metabolic Health 1 T – 5mg GLP-1 T - 30 mg

In this population: Higher waist-to-hip ratio increased risk up to 7.7-fold (especially peri-menopausally) Greater body fat percentage, waist-height ratio, or visceral fat area each increased risk around 4-fold Higher body mass index (BMI) or waist circumference, each, increased risk almost 3-fold Because obesity is associated with significant changes in immunometabolic and hormonal parameters, it seems likely that the strength of these findings will be confirmed in other populations

Lu Author profile: Cedars-Sinai Research Profile Shelly C

You still need strength training

Mounjaro injections are also taken once weekly and, despite only currently being approved by the FDA for diabetes, have shown the most impressive weight loss numbers of any GLP1 drug approved by the FDA in general

The hallmarks of cancer

Important discussion points include: Medical history : Disclose any history of thyroid problems (especially MTC), MEN2, pancreatitis, gallbladder disease, kidney disease, gout, liver disease, or alcohol use Treatment goals : Clarify whether niacin therapy is necessary given current lipid management guidelines, which generally favor statins, ezetimibe, PCSK9 inhibitors, or other agents before niacin for cardiovascular risk reduction Glucose monitoring plan : Establish a clear schedule for blood glucose checks and hemoglobin A1c testing (typically every 3 months) to assess the combination's net effect on glycemic control Liver monitoring plan : Discuss the schedule for liver function tests if taking pharmacologic doses of niacin (baseline, 6-8 weeks during titration, and periodically thereafter) Pregnancy planning : If applicable, discuss contraception needs, as tirzepatide may reduce oral contraceptive effectiveness during initiation and dose escalation Symptom management : Review strategies for managing potential side effects from both medications, including the timing of niacin doses to minimize flushing and approaches to mitigate tirzepatide's gastrointestinal effects Patients should specifically ask about the expected timeline for therapeutic effects, warning signs that require immediate medical attention (severe abdominal pain, yellowing of skin/eyes, unusual fatigue, neck swelling), and whether any dose adjustments to existing diabetes medications may be necessary